TRACERx MRD Results Showcase ppmSeq’s Ultra-Sensitive ctDNA Detection at AACR

Why It Matters

Achieving parts‑per‑million ctDNA detection with whole‑genome sequencing removes a major barrier to routine MRD testing, potentially accelerating early relapse intervention and reducing reliance on custom assays.

Key Takeaways

• ppmSeq detects ctDNA at low single‑digit ppm sensitivity.
• TRACERx pilot validated ppmSeq on 50 plasma samples.
• Specificity >99.9% in 120 non‑cancer donor samples.
• Limit of detection below 3 ppm across 13 concentrations.
• Whole‑genome MRD monitoring becomes scalable without bespoke assays.

Pulse Analysis

Minimal residual disease (MRD) monitoring is a linchpin in modern oncology, offering clinicians a window into microscopic disease that can herald relapse. Traditional MRD assays rely on bespoke panels tailored to each patient’s tumor mutations, a process that is labor‑intensive and costly. Whole‑genome sequencing (WGS) promises a universal approach, but until now it has struggled to match the sensitivity of targeted methods. Ultima Genomics’ ppmSeq technology bridges that gap, delivering single‑digit parts‑per‑million ctDNA detection, a threshold previously thought exclusive to custom assays.

The TRACERx pilot, presented at AACR, leveraged over 3,200 tumor samples from 800 lung‑cancer patients to identify patient‑specific variants for plasma testing. In a cohort of 50 plasma samples, ppmSeq achieved high analytical sensitivity, while an independent Labcorp study confirmed >99.9% specificity across 120 healthy donors and a limit of detection below 3 ppm across 13 concentration levels. These results demonstrate that WGS can reliably differentiate cancerous from non‑cancerous plasma, reducing false‑positive rates that have hampered broader clinical adoption. The ability to monitor MRD at such low thresholds could enable earlier therapeutic interventions and more precise treatment de‑escalation.

For the biotech market, ppmSeq’s performance signals a shift toward scalable, off‑the‑shelf MRD solutions. By eliminating the need for bespoke assay development, hospitals and diagnostic labs can streamline workflows, cut costs, and accelerate turnaround times. Ultima Genomics positions itself as a key enabler for national health systems like the NHS to implement genome‑wide MRD monitoring at scale. As regulatory pathways mature and reimbursement models adapt, the technology could become a standard component of oncology care, driving both improved patient outcomes and new revenue streams for genomic service providers.